Thus, the early detection of EGFR and KRAS mutations can facilitate the selection of treatment modalities for specific mutation types and enable efficient short- and long-term management, thus improving the prognosis and prolonging the survival duration of patients with NSCLC [4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.